Aiming to uncover the mechanism and possible treatment of chronic diseases like metabolic disorder and cancer, our platform was founded in 2017 by three research groups in this field. The Laboratory mainly focuses on three topics, first is the molecular basis of insulin resistance and beta cell dysfunction, as well as the relationship between chronic inflammation and insulin resistance; second is metabolic disorder promoting maintenance of tumor stemness and third is tumor hypoxia related signaling pathways causing tumorigenesis.
Our platform currently consists of 10 members and is supported by multiple grants. These grants are from some National and local programs and science foundations. Total grants have exceeded RMB 30 million. We have more than 63 publications in recent 5 years, the total impact factors are over 624 and the average is 9.89. Eight of them were published in journals with an impact factor over 20, eighteen of them are 10-20, and 26 of them are 5-10. Collectively 16 patents have been applied for or received by the platform members and they also participate in the draft of 12 academic books. Finally, several small molecule compounds originating from natural products and lead peptides/monoclonal antibodies that can break key protein interactions are in preclinical developments, and are expected to be submitted as new drug candidates in 2022.
